Peptide/Protein Ingredients TRIZ Cases

Small-molecule PSMA PET tracers improve tumor-to-muscle ratios through faster blood clearance, enabling more accurate prostate cancer imaging.

Specific polysorbate-20, trehalose, and arginine levels keep anti-IL5R antibodies stable in water, avoiding lyophilization and reconstitution.

A hyaluronidase-based anti-CD38 formulation improves subcutaneous dose delivery by overcoming antibody solubility and liquid stability limits.

Microbial glycogen debranching genes fit AAV limits while dual promoters and codon optimization reduce immune response in GSD III therapy.

Hyaluronidase enables subcutaneous delivery of anti-PD-1 or anti-PD-L1 antibodies, reducing reliance on invasive IV tumor treatment.

A three-stage culture process converts feline adipose stromal cells into insulin-secreting β cells for durable glucose control without daily injections.

Esculentin peptides help restore mutant CFTR chloride transport, rebalance periciliary liquid, and reduce infection burden in cystic fibrosis.

A purified canine mite extract enriches Der f 15 and Der f 18 while reducing Der f 1 and Der f 2 to improve allergy immunotherapy specificity.

Closed-loop patch pumps use glucose feedback, glucagon delivery, and flexible cannula layouts to reduce user input in diabetes care.

Combining CER-modified CD4+ and CAR/TCR-modified CD8+ T cells improves solid tumor killing while supporting immune cell persistence.

High-affinity FOLR1 binding proteins enable more specific cancer imaging and radiotherapy where conventional treatment faces resistance.

Co-administering a DKK1 antibody with VEGF or VEGFR inhibition addresses resistant colorectal cancer by targeting key pathways and improving outcomes.

Dimeric EphA2-targeting peptide mimetics trigger lysosomal receptor degradation and selectively deliver chemotherapy to resistant cancer cells.

Selective bispecific antigen binding activates normal T cells against T cell tumors while reducing immunodeficiency from CD3-directed therapy.

A swellable microneedle structure uses intestinal peristalsis to cross the gut wall, improving biologic oral delivery with safer retention.

Using koji mold lipase and cellulase, this case shows how one enzyme composition can raise both Bifidobacterium and Lactobacillus in the intestine.

A protrusion-and-slot plunger lock enables syringe priming and accurate VEGF antagonist dosing while silicone-free packaging supports sterile handling.

Modified GRPR-targeted peptides improve metabolic stability and imaging while reducing pancreas uptake in GRPR-expressing cancers.

A newly identified lncRNA-encoded HMBJ micropeptide suppresses key fibrosis markers, enabling diagnosis and treatment of organ fibrosis.

A micropeptide MIAC case showing how one peptide suppresses tumor cell proliferation and migration across diverse cancers.

Combining LAG-3 antagonism, PD-1 inhibition, and chemotherapy improves immune activation and tumor suppression in gastric and GEJ cancer.

LCOR mutants lacking the nuclear receptor binding domain restore APM gene expression in TNBC stem cells, improving response to ICB and ACT.

Antigen-triggered FOXO1 or TCF7 expression helps engineered T cells proliferate while controlling exhaustion and differentiation in solid tumors.

User override feedback and continuous glucose data let insulin dosing adapt automatically, reducing recalibration and decision burden.

A controlled-release CNP agonist maintains therapeutic levels for at least 6 hours, avoiding continuous infusion and reducing hypotension risk.

Targets conserved CX/HY glycans on influenza envelopes to neutralize H1N1, H5N1, H7N9, and other mutating strains.

pTalpha restores CD3 function in TCR-deficient donor T cells, enabling expansion and standardized CAR immunotherapy with lower GVHD risk.

A 3E10 antibody fragment fused to Hsp or GRP78 carries therapeutic proteins into cells through hENT2, enabling intracellular protection from ROS toxicity.

Blocking KRAS G12V binding to JAK1 with peptides or small molecules can reverse immune escape and improve checkpoint inhibitor response.

Engineered CD4+ T cells co-express IL-10 and CARs to scale regulatory cell therapy while preserving immune suppression and targeted killing.

Rationally modified T-cell epitopes replace crude allergen extracts to improve desensitization while lowering anaphylactic risk.

Intravenous fat emulsion given before or after intraoperative hypotension helps reduce myocardial injury, acute kidney injury, and mortality.

Transglutaminase anchors myostatin inhibitors to the extracellular matrix to prevent rapid clearance, extend local action, and improve wound repair.

Targeting GRP78 with ISM1 polypeptides induces alveolar macrophage apoptosis to resolve lung inflammation and help preserve lung homeostasis.

Mitochondrial-derived peptide analogs induce autophagy, lower tumor cell viability, and reduce tumor size while sparing healthy cells.

Disaggregated muscle fiber fragments with retained satellite cells help reverse rotator cuff atrophy and rebuild functional shoulder muscle.

Agrin peptide treatment drives adult cardiomyocyte cell cycle reentry to reduce scarring and restore cardiac function after injury.

Genetically modified hematopoietic cells evade CAR T recognition, reducing fratricide and off-tumor toxicity while preserving blood cell function.

Combining VEGF and PD-1/PD-L1 inhibitors improves response in cancers unresponsive to checkpoint inhibitor treatment alone.

Targeting αvβ5 integrin-positive tumor Tregs with iRGD improves PDAC checkpoint response while avoiding systemic autoimmune effects.

Activated CD44 targeting with hyaluronic acid liposomes raises drug levels at vulnerable plaques while sustaining release and limiting systemic side effects.

Localized IL-12 expression from lipopolymer nanoparticles with anti-VEGF improves tumor response while reducing systemic toxicity.

Direct tumor injection of L19-huTNFα and L19-huIL2 shrinks non-melanoma skin tumors and avoids disfiguring surgery.

Engineered T cells targeting MAGE-A4 aim to improve head and neck tumor response while reducing checkpoint inhibitor dose and side effects.

Removing the nucleus creates therapeutic cells that deliver biomolecules while avoiding uncontrolled proliferation and unwanted DNA transfer.

A closed renal artery-vein perfusion loop concentrates AAV therapy in the kidney while limiting systemic leakage and improving delivery uniformity.

Local anesthetics combined with extracellular matrix components deliver pain relief and numbing within 300 seconds while avoiding opioid-related side effects.

Novel Formula I compounds irreversibly crosslink PRX3 cysteines to raise mitochondrial ROS, improving solubility and synthesis over thiostrepton.

A sequence-defined peptide activates tyrosinase in melanocytes to boost melanin synthesis and restore pigmentation without UVB or steroid side effects.

Disc stack centrifugation plus cold flocculation and depth filtration cuts turbidity and filter clogging in high-PCV perfusion harvests.